Investing.com - Amylyx Pharmaceuticals reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Amylyx Pharmaceuticals announced earnings per share of $-0.92 on revenue of $350K. Analysts polled by Investing.com anticipated EPS of $-0.93 on revenue of $1.42M.
Amylyx Pharmaceuticals shares are down 28.35% from the beginning of the year, still down 8.71% from its 52 week high of $38.76 set on October 25.
Amylyx Pharmaceuticals follows other major Healthcare sector earnings this month
Amylyx Pharmaceuticals's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar